Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Aug;9(4):511-513.
doi: 10.21037/hbsn.2019.11.27.

Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease

Valentina Cossiga  1 , Maria Guarino  1 , Filomena Morisco  1 , Nicola Caporaso  1
Affiliations
Editorial

Risk stratification of HCC occurrence after HCV eradication: a complicate plot of risk factors related and unrelated to the previous viral disease

Valentina Cossiga et al. Hepatobiliary Surg Nutr. 2020 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/hbsn.2019.11.27). The authors have no conflicts of interest to declare.

Comment on

References

    1. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. 10.1016/j.jhep.2018.03.019 - DOI - PubMed
    1. Global Burden of Disease Liver Cancer Collaboration , Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91. 10.1001/jamaoncol.2017.3055 - DOI - PMC - PubMed
    1. Everson GT, Jensen DM, Craig JR, et al. Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics. Hepatology 1999;30:271-6. 10.1002/hep.510300116 - DOI - PubMed
    1. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166:637-48. 10.7326/M16-2575 - DOI - PMC - PubMed
    1. Singer AW, Reddy KR, Telep LE, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87. 10.1111/apt.14593 - DOI - PubMed